Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
lanadelumab-flyo, Takhzyro
Synonyms :
lanadelumab
Class :
Kallikrein Inhibitors
Brand Name :
lanadelumab-flyo, Takhzyro
Synonyms :
lanadelumab
Class :
Kallikrein Inhibitors
Dosage forms and strengths
(Injectable solution)
300mg/2mL(150mg/mL)
prefilled syringe or single-dose vial
Administer 300 milligrams subcutaneously every two weeks
If the patient has been free from attacks for more than six months and is well-controlled
considering a dosing interval of 300 mg subcutaneously every four weeks can be an effective option
Dosage forms and strengths
(Injectable solution)
300mg/2mL (150mg/mL, single-dose vial)
150mg/mL (single-dose prefilled syringe)
300mg/2mL (150mg/mL, single-dose prefilled syringe)
Age 2 to <6 years- Administer a subcutaneous dose of 150 mg every four weeks
Age 6 to <12 years-The recommended dosage for subcutaneous administration is 150 mg every two weeks
In cases where the patient has achieved good control of symptoms, such as being free from attacks, for a period of more than six months, the dosing interval can be considered as 150 mg every four weeks
Age ≥12 years-The recommended dosage is 300 mg subcutaneously every two weeks
Refer adult dosing
it may enhance the adverse effects when combined with aducanumab
Actions and Spectrum
Action:
The drug acts by binding to plasma kallikrein and preventing its activity. By inhibiting plasma kallikrein, drug reduces the production of bradykinin, which helps to prevent episodes of swelling and angioedema associated with HAE. It effectively blocks the bradykinin-mediated cascade, providing a sustained and preventative effect.
Spectrum:
The drug is specifically indicated for the prophylaxis of attacks in patients with HAE. It is not intended for the treatment of acute HAE attacks but rather for long-term prevention. By targeting plasma kallikrein, drug offers a broad-spectrum approach to HAE management, regardless of the underlying genetic mutation causing the condition. It has shown efficacy in reducing the frequency and severity of HAE attacks when administered as a prophylactic treatment.
Frequency defined
>10%
(300 mg q2Week dosing)
Headache (33%)
Upper respiratory tract infection (44%)
Injection site reaction (56%)
Myalgia (11%)
(300 mg q4Week dosing)
Headache (21%)
Upper respiratory tract infection (31%)
Injection site reaction (45%)
1-10%
Hypersensitivity (1%)
Increased AST or ALT (2%)
(300 mg q2Week dosing)
Rash (4%)
Diarrhea (4%)
Dizziness (4%)
(300 mg q4Week dosing)
Dizziness (10%)
Rash (10%)
Black Box Warning:
None
Contraindication/Caution:
Hypersensitivity: Individuals with a known hypersensitivity or allergy to lanadelumab or any of its components should not use this medication.
Acute HAE attacks: The drug is not intended for the treatment of acute HAE attacks. It is specifically used for prophylactic (preventive) treatment and should not be administered during an ongoing attack.
Severe hepatic impairment: The drug is metabolized in the liver, and individuals with severe hepatic impairment may have altered drug metabolism. It is important to exercise caution and consider alternative treatment options in such cases.
Immunodeficiency: Due to its mechanism of action, drug may affect the immune system. Individuals with severe immunodeficiency or receiving immunosuppressive therapy should use this medication with caution.
Pregnancy warnings:
Pregnancy category: N/A
Lactation: Excreted into human milk is unknown
Pregnancy Categories:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
lanadelumab is a type of monoclonal antibody prescribed to individuals aged 12 and above to prevent attacks of hereditary angioedema (HAE).
Pharmacodynamics:
The drug binds specifically to plasma kallikrein, an enzyme involved in the production of bradykinin. Bradykinin is a key mediator of angioedema attacks in patients with HAE. By inhibiting plasma kallikrein, drug reduces the production of bradykinin, thereby preventing angioedema attacks.
Pharmacokinetics:
Absorption
The drug is administered via subcutaneous injection. After injection, it is absorbed into the systemic circulation.
Distribution
The drug is a monoclonal antibody and, as such, has a large molecular weight. It is expected to distribute primarily within the vascular compartment. The volume of distribution is influenced by factors such as body weight and the target tissue’s characteristics.
Metabolism
Monoclonal antibodies like lanadelumab are not extensively metabolized in the body.
Excretion and Elimination
The elimination of this drug primarily occurs via proteolytic degradation in tissues and cells. The exact clearance mechanisms and elimination half-life may vary among individuals.
Administration:
Before administering the injection, cleanse the injection site using an alcohol wipe and ensure it is completely dry.
Administer the full dose subcutaneously (SC) in the abdomen, thigh, or upper arm. It is important for a caregiver to perform the injection.
Patient information leaflet
Generic Name: lanadelumab
Why do we use lanadelumab?
Prevention of HAE Attacks: The drug is primarily prescribed as a prophylactic treatment to prevent HAE attacks. It works by inhibiting the activity of an enzyme called plasma kallikrein, which is involved in the production of bradykinin, a substance that causes swelling and inflammation in HAE.
Long-Term Management: The drug is designed for long-term use to provide ongoing prevention of HAE attacks.
Reduction of HAE Attack Frequency: By regularly using lanadelumab, patients with HAE can experience a significant reduction in the frequency and severity of their attacks. It helps to maintain a lower level of bradykinin in the body, thereby minimizing the occurrence of swelling episodes.
Improvement in Quality of Life: HAE attacks can be painful, unpredictable, and disruptive to daily life. lanadelumab treatment aims to improve the quality of life for individuals with HAE by minimizing the impact of symptoms, reducing the need for emergency medical interventions, and allowing for better planning and participation in regular activities.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
